Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price target lifted by analysts at Canaccord Genuity Group from $85.00 to $90.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 14.36% from the company’s previous close.

A number of other equities research analysts have also issued reports on ESTA. Needham & Company LLC upped their target price on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho upped their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday. Stephens lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Citigroup raised their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Establishment Labs Price Performance

Establishment Labs stock opened at $78.70 on Thursday. The firm has a market capitalization of $2.29 billion, a PE ratio of -45.23 and a beta of 0.99. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $83.31. The firm’s 50-day simple moving average is $71.30 and its 200 day simple moving average is $58.32. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.19) earnings per share. On average, equities research analysts predict that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the last quarter. CWM LLC boosted its holdings in shares of Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after purchasing an additional 686 shares during the last quarter. Pier Capital LLC purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at $10,777,000. Milestone Asset Management LLC acquired a new stake in shares of Establishment Labs during the 2nd quarter worth $523,000. Finally, Tyro Capital Management LLC raised its position in shares of Establishment Labs by 0.3% in the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company’s stock worth $45,560,000 after buying an additional 2,835 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.